Subscribe
Business

FDA delays decision on Pfizer, Bristol-Myers drug

By The Associated Press
Published
Add Washington Examiner on Google

Federal regulators are again delaying a decision on whether to approve the highly touted experimental anticlotting drug Eliquis developed by Pfizer and Bristol-Myers Squibb.

The drugmakers say the Food and Drug Administration is asking for more information from a huge international study that examined stroke prevention in patients with an irregular heartbeat called atrial fibrillation. The companies say regulators are not asking for any new studies.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.